Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

  • Brieflands is a Registered Trademark with record number 1454012.
  • Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
  • Nedmedica is our related company which is specialized in Author Services. 
  • Our former branding name was Kowsarmedical Publishing (2010-2021).

  • Long-term Follow-up of Patients Treated with Whole-Breast External Beam Radiotherapy or Intraoperative Radiotherapy After Breast-Conserving Surgery
    (Brieflands, 2026-12-31)
    Farzam Shahpouri
    ;
    Farzin Roozafzai
    ;
    Atieh Akbari
    ;
    Mehrdad Daliri
    ;
    Mohammad Esmaeil Akbari
    Background: Breast-conserving surgery with radiotherapy is the standard treatment for breast cancer. Because of the duration and complications of external beam radiotherapy (EBRT), patients may prefer mastectomy. Intraoperative radiotherapy (IORT) shortens treatment duration and may reduce radiation-related complications. Objectives: To investigate whether IORT was noninferior to EBRT by assessing breast cancer recurrence during follow-up among patients treated at a single research center. Methods: In this prospective cohort, 9,749 patients were followed for up to 10 years after breast-conserving surgery and radiotherapy. The outcome was breast cancer recurrence. External beam radiotherapy was delivered to 8,812 participants. Intraoperative radiotherapy was administered according to the Iranian IORT consensus criteria. A total of 541, 305, 66, and 25 patients received boost intraoperative electron radiotherapy (IOeRT), radical IOeRT, boost intraoperative 50 kV X-ray radiotherapy (IOxRT), and radical IOxRT, respectively. Independent-samples t tests, chi-square tests, and Fisher's exact tests were used to compare patients with and without recurrence. Predictors of recurrence were evaluated using univariate and multivariate logistic regression. Kaplan-Meier analysis assessed recurrence-free survival. Results: During follow-up, breast cancer recurred in 353 participants. Among these patients, the mean time to recurrence was 40.5 months (95% confidence interval, 37.0 - 44.0). Recurrence rates were 3.67% in the EBRT group and 3.09% in the IORT group, with no significant difference (P = 0.408). Within the IORT group, recurrence rates were 4.6% after boost IOeRT and 1.3% after radical IOeRT; no recurrences occurred after boost or radical IOxRT. Disease-free survival was comparable between EBRT and boost IOeRT but was better after IOxRT and radical IOeRT. Conclusions: Intraoperative radiotherapy was noninferior to EBRT. Boost IOeRT yielded outcomes comparable to those of EBRT, whereas IOxRT and radical IOeRT were associated with lower recurrence rates and improved disease-free survival, supporting their use.